星空游戏网站免费进入|星空彩票电脑版

Abstract

Abstract:

It is traditionally thought that anxiety disorder and depressive disorder are categorically defined as two individual psychiatric disorders. As clinical practice and epidemiological studies show，however，the comorbidity of depression and anxiety is prevalent and of poorer outcomes than either disorder alone. In this review，the concepts，clinical features，therapeutic managements，and animal models related to the comorbidity of depression and anxiety are well addressed. In addition，establishing the novel animal models and developing the new agents of both anti-depression and-anxiety are discussed to improve its diagnosis，treatment，and medical prevention.

Key words:anxiety,depression,comorbidity,animal model

CLC Number:

R964

Cite this article

LIANG Hui，CHENG Tao，LIANG Jian-hui.Progress in the Comorbidity of Depression and Anxiety[J]. Acta Neuropharmacologica,DOI: 10.3969/j.issn.2095-1396.2017.06.005.

share this article

0
/Recommend

Add to citation managerEndNote|Ris|BibTeX

URL:http://actanp.hebeinu.edu.cn/EN/10.3969/j.issn.2095-1396.2017.06.005

http://actanp.hebeinu.edu.cn/EN/Y2017/V7/I6/30

References

[1]Tabatha H Melton, Paul E Croarkin, Jeffrey R Strawn,et al.Comorbid anxiety and depressive symptoms in children and adolescents: a systematic review and analysis[J].J Psychiatr Pract, 2016, 22(2):84-98.

[2]Katharina Kircanski, Joelle LeMoult, Sarah Ordaz,et al.Investigating the nature of cooccurring depression and anxiety: Comparing diagnostic and dimensional research approaches[J]. J Affect Disord, 2017, 16:123-135.

[3]Amanda L Rebar, Rob Stanton, Simon Rosenbaum.Comorbidity of depression and anxiety in exercise research[J]. Lancet Psychiatry, 2017, 4(7): 519.

[4]Alvan R Feinstein.The pre-therapeutic classification of co-morbidity in chronic disease[J]. J Chronic Dis, 1970, 23(7): 455-468.

[5]Jules Angst.Depression and anxiety: implications for nosology, course, and treatment[J]. J Clin Psychiatry, 1997, 58(Suppl 8): 3-5.

[6]Van Praag H M.Comorbidity (psycho) analysed[J]. Br J Psychiatry Suppl, 1996, 30: 129-134.

[7]Ron de Graaf, Rob V Bijl, Filip Smit,et al.Risk factors for 12?monthcomorbidity of mood, anxiety, and substance use disorders: fndings from the Netherlands Mental Health Survey and Incidence Study[J]. Am J Psychiatry, 2002, 159(4): 620?629.

[8]Robert Johansson, Per Carlbring, Asa Heedman,et al.Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life[J]. Peer J, 2013, 1:e98.

[9]Michael R Phillips, Zhang Jing-xuan, Shi Qi-chang,et al.Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001?05: An epidemiological survey[J]. Lancet, 2009, 373(9680): 2041?2053.

[10]Arjan W Braam, John R M Copeland, Philippe A E G Delespaul,et al.Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: results from the EURODEP concerted action[J]. J Affect Disord, 2014, 155: 266-272.

[11]Colleen M Cummings, Nicole E Caporino, Philip C Kendall.Comorbidity of anxiety and depression in children and adolescents: 20 years after[J]. Psychol Bull, 2014, 140(3): 816-845.

[12]Ahmet Koyuncu, Erhan Ertekin, Banu Aslantas Ertekin,et al.Relationship between atypical depression and social anxiety disorder[J]. Psychiatry Res, 2015, 225(1-2): 79-84.

[13]Idan M Aderka, Courtney Beard, Josephine Lee,et al.The relationship between depression and generalized anxiety during intensive psychological and pharmacological treatment[J]. J Affect Disord, 2015, 184: 261-268.

[14]Jesper T Andreasen, Ciaran M Fitzpatrick, Maria Larsen,et al.Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action[J]. Brain Res, 2015, 1601: 117-126.

[15]Aravind Mittur.Trazodone: properties and utility in multiple disorders[J]. Expert Rev Clin Pharmacol, 2011, 4(2): 181-196.

[16]Rickels K, Downing R, Schweizer E,et al.Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam[J]. Arch Gen Psychiatry, 1993, 50(11): 884-895.

[17]Fawcett J, Barkin R L.A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety[J]. J Clin Psychiatry, 1998, 59(3): 123-127.

[18]Sarawut Lapmanee, Jantarima Charoenphandhu, Narattaphol Charoenphandhu.Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors[J]. Behav Brain Res, 2013, 250: 316-325.

[19]Kostowski W, Dyr W, Krzascik P,et al.5-Hydroxytryptamine1A receptor agonists in animal models of depression and anxiety[J]. Pharmacol Toxicol, 1992, 71(1): 24-30.

[20]Sramek J J, Tansman M, Suri A,et al.Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms[J]. J Clin Psychiatry, 1996, 57(7): 287-91.

[21]王宪军,王振英.丁螺环酮与文拉法新联合治疗抑郁焦虑共病对照研究[J].新乡医学院学报, 2004, 21(5): 407-408.

[22]Richard C Shelton, Gary D Tollefson, Mauricio Tohen,et al.A novel augmentation strategy for treating resistant major depression[J]. Am J Psychiatry, 2001, 158(1):131-134.

[23]王坚.从胆论治冠心病后焦虑、抑郁症[J].中国社区医师:医学专业, 2010, 12(7): 93-94.

[24]李克建，陈云，郭娟，等.疏肝解郁胶囊联合草酸艾司西酞普兰治疗脑卒中患者焦虑抑郁状态的疗效观察[J].国际精神病学杂志, 2017, 44(2): 260-262+266.

[25]宋波,朱功蓓,林煜涵,等.解虑安神汤对焦虑小鼠脑内GABA水平及其受体表达的影响[J].中药药理与临床, 2013, 29(6): 118-121.

[26]郭岳峰刘方洲.解郁安神汤抗抑郁作用的实验研究[J].中医研究, 2010, 23(10): 24-26.

[27]尹东辉,张晶,刘纯莉.乌灵胶囊的临床应用进展[J].中国新药杂志,2011, 20(16)：1530-1533+1562

[28]Jean-Philippe Boulenger, M Fournier, D Rosales,et al.Mixed anxiety and depression: from theory to practice[J]. J Clin Psychiatry, 1997, 58(Suppl 8): 27-34.

[29]Colleen Stiles-Shields, Mary J Kwasny, Cai Xuan,et al.Comorbid anxiety as a differential treatment predictor for telephone versus face-to-face administered cognitive behavioral therapy for depression[J]. Depress Anxiety, 2014, 31(11): 934-940.

[30]Dilip Kumar Pandey, Sushil Kumar Yadav, Radhakrishana Mahesh,et al.Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety?[J].Behav Brain Res, 2009, 205(2):436-442.

[31]Liu Yu-ting, Shao Yen-wen, Yen Chen-tung,et al.Acid-induced hyperalgesia and anxio- depressive comorbidity in rats[J]. Physiol Behav, 2014, 131: 105-110.

[32]Kenneth J Sufka, Matthew Feltenstein, Jason EWarnick,et al.Modeling the anxiety-depression continuum hypothesis in domestic fowl chicks[J]. Behav Pharmacol, 2006, 17(8): 681-689.

[33]Ana M Basso, Kelly B Gallagher, Natalie A Bratcher,et al.Antidepressant- like effect of D (2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test[J]. Neuropsy-chopharmacology, 2005, 30(7):1257-1268.

[34]Rodrigo Moraga-Amaro, Hugo Gonzalez, Rodrigo Pacheco,et al.Dopamine receptor D3 deficiency results in chronic depression and anxiety[J]. Behav Brain Res, 2014, 274: 186-193.

[35]Lucien Steru, Raymond Chermat, Bernard Thierry,et al.The tail suspension test: a new method for screening antidepressants in mice[J]. Psychopharmacology (Berl),1985, 85(3):367-370.

[36]Malika El Yacoubi, Saoussen Bouali, Daniela Popa,et al.Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression[J]. Proc Natl Acad Sci U S A, 2003, 100(10):6227-6232.

[37]Malika El Yacoubi, Virginie Rappeneau, Eddy Champion,et al.The H/Rouen mouse model displays depression-like and anxiety-like behaviors[J]. Behav Brain Res, 2013, 256:43-50.

Catherine S John, Elizaheth I Sypek, William A Carlezon,et al.Blockade of the GLT-1 transporter in the central nucleus of the amygdala induces both anxiety and depressive-like symptoms[J]. Neuropsychopharmacology, 2015, 40(7):1700-1708.

Related Articles15

[1]	LI Jia-jie, LIU Jin-xing, ZHOU Ze, WANG Ya-ping, LIAO Jia-bao, LUO Cheng, YAN He-guo, LI Hong-mei, LI Qin, WEN Wei-bo.Research on the Animal Model of Type 2 Diabetes Mellitus with Damp-Heat Syndrome in Combination with Disease Evidence: A Review[J]. ACTA NEUROPHARMACOLOGICA, 2025, 15(3): 38-.
[2]	LI Xiao-dan, CHEN Ming, ZHENG Ying, WANG Zhi-jian, HUANG Ren-chun.Effects of Sertraline Combined with CCBT on Clinical Symptoms and Self-Care Abilities in Patients with Post-Schizophrenia Depression[J]. ACTA NEUROPHARMACOLOGICA, 2025, 15(1): 19-.
[3]	ZHANG Wei-jian, ZHAO Yun-hao, JIA Chong-ning, QIN Xue-mei, TIAN Jun-sheng.Research Progress on the Treatment of Depression with Chinese Medicine by Regulating Brain Sex Hormone Microenvironment Homeostasis[J]. ACTA NEUROPHARMACOLOGICA, 2025, 15(1): 25-.
[4]	ZHOU Xin-mei, ZHU Li-ping.Network Pharmacology Study of Sini SAN in the Treatment of Post-Stroke Depression[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 19-.
[5]	ZHANG Ran-ran, WU Zhi-gang.Research Progress of Neuroactive Steroid in the Treatment of Depression[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(1): 49-.
[6]	HUANG He, LAN Yue-ying.Clinical Efficacy of Amsulpride Combined with Duloxetine in Treatment of Depression in Forced Detoxification Patients[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(5): 43-.
[7]	HUANG Yu-li, LI Xiang-bo, YUAN li, TENG Jin-liang.Research Progress on Clinical Efficacy and Adverse Reactions of Esketamine[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(4): 13-.
[8]	WANG Qian-ru, HOU Jiu-wen, MEI Qi-bing.Research Progress on Animal Models of Human Kidney Disease[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(4): 29-.
[9]	NIU Cong, WU Zhi-gang.Research Progress of Traditional Chinese Medicine in the Treatment of Depression[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(1): 49-.
[10]	CUI Pei, SUN Yu-jiao, CHEN Jing-jing, ZHANG Xin-yu, DONG Yan-hong.Research Progress on the Application of Accelerated Repetitive Transcranial Magnetic Stimulation[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(3): 23-.
[11]	ZHAO Bo, YU Ai-mei, ZOU Yu-an.Research Progress of Cortical Spreading Depression[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(3): 28-.
[12]	WEI Yuan-yuan, ZHANG Yan-nan, FAN Yi-meng, GA Yu, WANG Hui-ru, HAN Jun-cheng, LV Jian-yu, HAO Zhi-hui.Comparative Study on Piglet Weaning Stress Syndrome and Diarrhea Type Irritable Bowel Syndrome with Liver Stagnation and Spleen Deficiency Syndrome[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(3): 44-.
[13]	LIAO Yu-mei, XUE Ya-dong, CHEN Sheng, et al. Research Progress of Anti-inflammatory Activity of PPARs Agonist in the Treatment of Depression[J]. ACTA NEUROPHARMACOLOGICA, 2021, 11(2): 32-38.
[14]	FAN Xukun, SUN Yi, SONG Shuangshuang, CONG Yifan, HOU Xueqin.Effects of Osthole on Cortical Neurotransmitters and the Anxietyand Depresion-Like Behaviors in the Oxytocin Receptor-Silencing Rats#br#[J]. ACTA NEUROPHARMACOLOGICA, 2021, 11(1): 11-17.
[15]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin.Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.

Metrics

Viewed

Full text

Abstract

Abstract
References
Related Articles
Recommended Articles
Metrics

TOP

Progress in the Comorbidity of Depression and Anxiety

PDF (PC)

Knowledge